Several Asian nations are quickly ramping up vaccination campaigns from shaky starts to combat growing Covid-19 infections, as supply shipments roll in and people overcome hesitancy in hopes of easing curbs and freeing up travel.
If you are not happy with the results below please do another search
50 search results for:
Shares of Theravance Biopharma rapidly declined after the company announced a Phase III cardiac drug failed to meet the study’s primary endpoint and a significant shift in its R&D efforts that resulted in a 75 percent staff termination.
The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Exkivity (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Imre has expanded the agency’s focus on earned activation with the addition of Bria Rooney as Vice President of Public Relations.
U.S. Food and Drug Administration scientists said on Sept. 15 that booster doses of Pfizer’s Covid-19 vaccine may not be needed, even though the third shot generates a higher immune response in recipients.
A study published in Nature Communications reveals that patients who had been hospitalized with severe Covid-19 might not be totally safe after recovery, as they are more likely to harbor self-attacking antibodies than those who did not have the virus.
IPG Health CEO Dana Maiman announced that Shaheed Peera joined FCB Health Europe as Global Creative Partner. Best known as founder of the Creative Floor Awards, in addition to other countless achievements, Peera will partner with creative leaders, championing collaboration, diversity & inclusion and continued unparalleled creative excellence across the FCB Health family of agencies.
Two weeks after winning U.S. approval as a treatment for adults with Waldenstrom’s macroglobulinemia, BeiGene’s Brukinsa scored again as a treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL).
According to a California WARN notice, Sanofi is shuttering Principia Biopharma’s laboratories in San Francisco and laying off about three dozen employees after the Phase III PEGASUS trial failure of rilzabrutinib for pemphigus.
With gender inequality a continued area of focus for corporations and workplaces around the globe, the Healthcare Businesswomen’s Association (HBA) recognized Merck & Co. Inc. and Otsuka America Pharmaceutical Inc. for exemplary workplace initiatives working to close the gender gap in the healthcare and life science industries.